X

Drug Profile

Cancer vaccine - Aixlie

Alternative Names: HER-2-VAX; HER-2/neu vaccine - Aixlie

Latest Information Update: 31 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ohio State University
Developer Aixlie Pharmaceuticals; Arkios BioDevelopment International; Ohio State University
Class Cancer vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Breast cancer

Most Recent Events

14 Aug 2003 Discontinued - Phase-I for Breast cancer in USA (unspecified route)
08 Feb 2001 HER-2-VAX^TM is available for licensing (http://hometown.aol.com/aixlie/)
28 Nov 2000 New profile

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com